Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Syros Pharmaceuticals, Inc. (SYRS)

4.5   0.08 (1.81%) 01-27 16:00
Open: 4.44 Pre. Close: 4.42
High: 4.59 Low: 4.37
Volume: 90,969 Market Cap: 91(M)

Technical analysis

as of: 2023-01-27 4:48:22 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.76     One year: 6.73
Support: Support1: 3.77    Support2: 3.04
Resistance: Resistance1: 4.94    Resistance2: 5.76
Pivot: 4.33
Moving Average: MA(5): 4.44     MA(20): 4.13
MA(100): 4.72     MA(250): 7.89
MACD: MACD(12,26): 0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 69.2     %D(3): 68.7
RSI: RSI(14): 61.6
52-week: High: 20.97  Low: 0.68
Average Vol(K): 3-Month: 116 (K)  10-Days: 144 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SYRS ] has closed below upper band by 38.8%. Bollinger Bands are 17.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.59 - 4.62 4.62 - 4.64
Low: 4.32 - 4.34 4.34 - 4.36
Close: 4.46 - 4.5 4.5 - 4.54

Company Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 27 Jan 2023
How Will the Market React to Syros Pharmaceuticals Inc (SYRS) Stock Getting a Bullish Rating - InvestorsObserver

Fri, 27 Jan 2023
Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ... - MarketBeat

Thu, 26 Jan 2023
Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Stock Drops -80.94 ... - Marketing Sentinel

Thu, 26 Jan 2023
2023-01-26 | NDAQ:SYRS | Press Release | Syros Pharmaceuticals ... - Stockhouse

Sun, 15 Jan 2023
Syros Pharmaceuticals A Buy Given Price, Pipeline Potential ... - Seeking Alpha

Mon, 09 Jan 2023
Syros Announces Clinical Updates and 2023 Strategic Priorities - Business Wire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 20 (M)
Shares Float 17 (M)
% Held by Insiders 1.5 (%)
% Held by Institutions 45.6 (%)
Shares Short 947 (K)
Shares Short P.Month 823 (K)

Stock Financials

EPS -1.55
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.38
Profit Margin (%) 0
Operating Margin (%) -534.7
Return on Assets (ttm) -31.8
Return on Equity (ttm) -96.7
Qtrly Rev. Growth -31.8
Gross Profit (p.s.) 1.16
Sales Per Share 1.15
EBITDA (p.s.) -6.05
Qtrly Earnings Growth 0
Operating Cash Flow -115 (M)
Levered Free Cash Flow -58 (M)

Stock Valuations

PE Ratio -2.91
PEG Ratio 0
Price to Book value 0.7
Price to Sales 3.88
Price to Cash Flow -0.8

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.